Lead Inventor:
Adolfo Ferrando, M.D., Ph.D.
Lymphoblastic leukemia models using T cell strain:
T-cell lymphoblastic leukemia (T-ALL) is a rare cancer of the immune system's own T-cells. A treatment for this cancer is needed. This technology provides CUTLL1 cells, which will be useful as an experimental model for T-ALL and for testing of therapeutic strategies.
Cells for lymphoblastic leukemia drug development :
Activating mutations in NOTCH1 are present in over 50% of human T-ALLs. This human T-cell lymphoma line CUTLL1, expresses high levels of activated NOTCH1 and is extremely sensitive to γ-secretase inhibitors treatment. CUTLL1 cells harbor a t(7;9)(q34;q34) chromosomal translocation which induces the expression of a TCRB-NOTCH1 fusion transcript encoding a membrane-bound truncated form of the NOTCH1 receptor.
Applications:
• Testing therapeutic strategies to treat T-ALL
Advantages:
• This technology provides a model system for the study of T-ALL
Patent Status: Copyright
Licensing Status: Copyright / Material available for Express Licensing
CUTLL1 cells
Publications:
CUTLL1, a novel human T-cell lymphoma line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Palomero, T et al. (2006) Leukemia. 20:1279-87.
